MPR Daily Dose Podcast #276 — Retatrutide Shows Significant Weight Loss; Hepcludex Approved; Acne Gel for OTC Use; Linzess Indication Expanded; Camizestrant Review Extended
New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to includ...
29 Touko 14min
MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked
US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains a...
15 Touko 11min
MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative
Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus...
8 Touko 9min
MPR Weekly Dose Podcast #273 — Gene Therapy Approved for Rare Hearing Loss; Pattern Hair Loss Tx Shows Growth; Brestri for Asthma; CRISPR gene for HAE; Novel Obesity Tx
Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene ...
1 Touko 13min
MPR Weekly Dose Podcast #272 — Idvynso Approved for HIV; Expanded Indication for Dupixent; Novel Tx Shows Promise for Pancreatic CA; Oral Semaglutide for Adolescents; GLP-1 Potential Knee OA Tx
Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral s...
24 Huhti 11min
MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion
Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use...
17 Huhti 14min
MPR Weekly Dose Podcast #270 — High Dose Wegovy; Durvalumab Combo for Unresectable HCC; Generic Dapagliflozin; Yuviwel Now Available for Achondroplasia
High-dose Wegovy now available for additional weight reduction when clinically indicated; trial results for durvalumab combo treatment in patients with unresectable hepatocellular; generic dapaglifloz...
10 Huhti 10min
MPR Weekly Dose Podcast #269 — Lifyorli, Avlayah Approved; Lyme Disease Vaccine Trial Results; Once-Weekly Basal Insulin Approved for T2DM
Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter syndrome and Awiqli gets approval as once-weekly basal insulin for type 2 ...
27 Maalis 10min
